CARE -A Retrospective, Dual-Cohort, 24-Week Real-World Study from the German Pain e-Registry on the Effectiveness and Safety of CBD-Dominant Oral Cannabis Extracts versus THC/Dronabinol in Older Patients with Chronic Pain". 1This study provides timely and high-level real-world evidence for a demographic-patients aged 65 years-that is historically underrepresented in clinical trials.The findings, particularly the 85.7% full response rate in the CBD-dominant cohort compared to 21.9% in the THC/DRO group, offer a compelling argument for the multidimensional benefits of CBD-rich formulations.We commend the authors for their rigorous methodology and valuable contribution to the field.To further enhance the clinical translation of these results, we wish to offer several methodological and clinical observations.
Qiang et al. (Sun,) studied this question.